The patients with CAF-derived CD9-positive EVs displayed a better five-year disease-free survival than patients with CD9-negative, indicating that CD9 expression in CAFs-EVs is a favorable prognostic marker for malignant melanoma patients (25). This evidence concerns the gene CD9 and melanoma.